Ruxolitinib in Combination With Autotransplant

Inclusion Criteria: * Histologically documented diagnosis of MF (idiopathic or post PV/ET) * Age 18-75 years * Intermediate-2/ high-risk disease as per Dynamic IPSS (DIPSS) criteria or Intermediate-1 risk disease with one of the following features within one year from screening: 1. Red cell transfusion dependency 2. unfavorable Karyotype 3. platelet count \<100 x 109/L 4. symptomatic splenomegaly 5. PB blasts \> 1% 6. Blasts in PB \<20% prior to study enrollment 7. No available suitable matched related (6/6 or 5/6) or unrelated donor (8/8 or 7/8 allele matched) or unwilling or unable to pursue allogeneic stem cell transplant 8. WBC \<50,000/ml at screening * Able to give informed written consent * ECOG Performance status of 0-2 * Life expectancy \>6 months * Off all myelofibrosis-related investigational or standard agents (except for ruxolitinib) for at least 4 weeks prior to study enrollment and recovered from all toxicities. If patient is already on ruxolitinib for a minimum of 16 weeks prior to study enrollment, patient can proceed to mobilization and collection * Adequate organ function defined as the following (\*unless clearly disease related): 1. Adequate renal function - creatinine \<2 x ULN 2. Adequate hepatic function - AST/ALT \<3 x ULN, Total Bilirubin \<3 x ULN, exception is elevated indirect bilirubin attributed to Gilbert's syndrome or hemolysis 3. Adequate hematopoietic function - Platelet ≥50 x 109/L (without transfusion) and ANC ≥1.0 x 109/L 4. LVEF \>40% (MUGA or echocardiogram) 5. Adequate pulmonary function with DLCO \>40% Exclusion Criteria: * Hypersensitivity to JAK inhibitor * Clinical evidence of cirrhosis * Leukemic transformation (\>20% blasts in PB or BM any time prior to HCT) * Platelet count \<50 x 109/L * Active uncontrolled infection * History of another malignancy within 5-years of date of HCT except history of basal cell or squamous cell carcinoma of skin or PV or ET * Known HIV positive * Woman of childbearing potential unwilling or unable to use adequate contraception Pregnant or nursing females Known active infection with hepatitis A, B or C virus